[Central serous chorioretinopathy--uptodate treatment options].
The review of literature is devoted to the uptodate treatment options of central serous chorioretinopathy.
K A
KA
Mirzabekova
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000628:therapy*; D006801:Humans; D017075:Laser Coagulation / Q000639:trends*; D010778:Photochemotherapy / Q000639:trends*; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab